entinostat has been researched along with Lung Neoplasms in 25 studies
Lung Neoplasms: Tumors or cancer of the LUNG.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Addition of entinostat to atezolizumab, carboplatin, and etoposide is unsafe and resulted in early onset and severe neutropenia, thrombocytopenia." | 5.69 | Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer, ETCTN 10399. ( Bullock, TN; Carducci, MA; Gentzler, RD; Hanley, M; Horton, B; Kim, K; Mock, J; Park, KS; Phelps, MA; Piekarz, R; Rhee, JC; Rudek, MA; Rudin, CM; Villaruz, LC, 2023) |
| "Entinostat is a selective HDAC inhibitor that has shown anti-neoplastic activity and tolerability in hematologic and solid tumors, including lung cancer." | 2.52 | Entinostat (SNDX-275) for the treatment of non-small cell lung cancer. ( Raez, LE; Rolfo, C; Ruiz, R, 2015) |
| " The subcutaneous dosing route for consecutive days and reduced bioavailability of 5-azacytidine because of inactivation by cytidine deaminase may limit the expansion of epigenetic therapy into Phase III trials." | 1.39 | Aerosolised 5-azacytidine suppresses tumour growth and reprogrammes the epigenome in an orthotopic lung cancer model. ( Belinsky, SA; Cheng, YS; Grimes, MJ; Kuehl, PJ; March, TH; Picchi, MA; Reed, MD; Tellez, CS; Tessema, M, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (12.00) | 29.6817 |
| 2010's | 19 (76.00) | 24.3611 |
| 2020's | 3 (12.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gentzler, RD | 1 |
| Villaruz, LC | 1 |
| Rhee, JC | 1 |
| Horton, B | 1 |
| Mock, J | 1 |
| Hanley, M | 1 |
| Kim, K | 1 |
| Rudek, MA | 2 |
| Phelps, MA | 1 |
| Carducci, MA | 1 |
| Piekarz, R | 1 |
| Park, KS | 1 |
| Bullock, TN | 1 |
| Rudin, CM | 3 |
| Solta, A | 1 |
| Boettiger, K | 1 |
| Kovács, I | 1 |
| Lang, C | 1 |
| Megyesfalvi, Z | 1 |
| Ferk, F | 1 |
| Mišík, M | 1 |
| Hoetzenecker, K | 1 |
| Aigner, C | 1 |
| Kowol, CR | 1 |
| Knasmueller, S | 1 |
| Grusch, M | 1 |
| Szeitz, B | 1 |
| Rezeli, M | 1 |
| Dome, B | 1 |
| Schelch, K | 1 |
| Hellmann, MD | 1 |
| Jänne, PA | 1 |
| Opyrchal, M | 1 |
| Hafez, N | 1 |
| Raez, LE | 2 |
| Gabrilovich, DI | 1 |
| Wang, F | 2 |
| Trepel, JB | 1 |
| Lee, MJ | 1 |
| Yuno, A | 1 |
| Lee, S | 1 |
| Brouwer, S | 1 |
| Sankoh, S | 1 |
| Wang, L | 1 |
| Tamang, D | 1 |
| Schmidt, EV | 1 |
| Meyers, ML | 1 |
| Ramalingam, SS | 1 |
| Shum, E | 1 |
| Ordentlich, P | 1 |
| Gurunathan, S | 1 |
| Kang, MH | 1 |
| Kim, JH | 1 |
| Luo, BL | 1 |
| Zhou, Y | 1 |
| Lv, H | 1 |
| Sun, SH | 1 |
| Tang, WX | 1 |
| Rao-Bindal, K | 2 |
| Koshkina, NV | 2 |
| Stewart, J | 1 |
| Kleinerman, ES | 3 |
| Murray-Stewart, T | 1 |
| Hanigan, CL | 1 |
| Woster, PM | 1 |
| Marton, LJ | 1 |
| Casero, RA | 2 |
| Reed, MD | 3 |
| Tellez, CS | 3 |
| Grimes, MJ | 3 |
| Picchi, MA | 3 |
| Tessema, M | 1 |
| Cheng, YS | 1 |
| March, TH | 3 |
| Kuehl, PJ | 1 |
| Belinsky, SA | 4 |
| Yokobori, T | 1 |
| Yokoyama, Y | 1 |
| Mogi, A | 1 |
| Endoh, H | 1 |
| Altan, B | 1 |
| Kosaka, T | 1 |
| Yamaki, E | 1 |
| Yajima, T | 1 |
| Tomizawa, K | 1 |
| Azuma, Y | 1 |
| Onozato, R | 1 |
| Miyazaki, T | 1 |
| Tanaka, S | 1 |
| Kuwano, H | 1 |
| Liu, Y | 2 |
| Oganesian, A | 1 |
| Taverna, P | 1 |
| Huang, G | 1 |
| Nishimoto, K | 1 |
| Yang, Y | 1 |
| Vendetti, FP | 2 |
| Topper, M | 1 |
| Huang, P | 1 |
| Dobromilskaya, I | 1 |
| Easwaran, H | 1 |
| Wrangle, J | 2 |
| Baylin, SB | 3 |
| Poirier, JT | 1 |
| Ruiz, R | 1 |
| Rolfo, C | 1 |
| Weintraub, K | 1 |
| Carter, CA | 1 |
| Zeman, K | 1 |
| Day, RM | 1 |
| Richard, P | 1 |
| Oronsky, A | 1 |
| Oronsky, N | 1 |
| Lybeck, M | 1 |
| Scicinski, J | 1 |
| Oronsky, B | 1 |
| Wang, S | 1 |
| Zhu, L | 1 |
| Zuo, W | 1 |
| Zeng, Z | 1 |
| Huang, L | 1 |
| Lin, F | 1 |
| Lin, R | 1 |
| Wang, J | 1 |
| Lu, J | 1 |
| Wang, Q | 1 |
| Lin, L | 1 |
| Dong, H | 1 |
| Wu, W | 1 |
| Zheng, K | 1 |
| Cai, J | 1 |
| Yang, S | 1 |
| Ma, Y | 1 |
| Ye, S | 1 |
| Liu, W | 1 |
| Yu, Y | 1 |
| Tan, J | 1 |
| Liu, B | 1 |
| Yong, KJ | 1 |
| Li, A | 1 |
| Ou, WB | 1 |
| Hong, CK | 1 |
| Zhao, W | 1 |
| Tatetsu, H | 1 |
| Yan, B | 1 |
| Qi, L | 1 |
| Fletcher, JA | 1 |
| Yang, H | 1 |
| Soo, R | 1 |
| Tenen, DG | 1 |
| Chai, L | 1 |
| Niesen, MI | 1 |
| Blanck, G | 1 |
| Kakihana, M | 1 |
| Ohira, T | 1 |
| Chan, D | 2 |
| Webster, RB | 1 |
| Kato, H | 1 |
| Drabkin, HA | 1 |
| Gemmill, RM | 1 |
| Mitchell, HD | 1 |
| Stidley, CA | 1 |
| Tesfaigzi, Y | 1 |
| Channell, MM | 1 |
| Witta, SE | 1 |
| Jotte, RM | 1 |
| Konduri, K | 1 |
| Neubauer, MA | 1 |
| Spira, AI | 1 |
| Ruxer, RL | 1 |
| Varella-Garcia, M | 1 |
| Bunn, PA | 1 |
| Hirsch, FR | 1 |
| Juergens, RA | 1 |
| Murphy, SC | 1 |
| Zhao, M | 1 |
| Coleman, B | 1 |
| Sebree, R | 1 |
| Rodgers, K | 1 |
| Hooker, CM | 1 |
| Franco, N | 1 |
| Lee, B | 1 |
| Tsai, S | 1 |
| Delgado, IE | 1 |
| Herman, JG | 1 |
| Brock, MV | 1 |
| Nagathihalli, NS | 1 |
| Massion, PP | 1 |
| Gonzalez, AL | 1 |
| Lu, P | 1 |
| Datta, PK | 1 |
| Moody, TW | 1 |
| Nakagawa, T | 1 |
| Kang, Y | 1 |
| Jakowlew, S | 1 |
| Jensen, RT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 1b/2, Open-label, Dose Escalation Study of Entinostat in Combination With Pembrolizumab in Patients With Non-small Cell Lung Cancer, With Expansion Cohorts in Patients With Non-small Cell Lung Cancer, Melanoma, and Mismatch Repair-Proficient Color[NCT02437136] | Phase 1/Phase 2 | 196 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| A Phase I Study to Assess the Food Effect on the Pharmacokinetics of Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic ER+ Breast Cancer and Men and Women With Progressive Non-Small Cell Lung Cancer[NCT01594398] | Phase 1 | 14 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| A Phase I Study of Entinostat in Combination With Enzalutamide for Treatment of Patients With Castration-Resistant Prostate Cancer[NCT03829930] | Phase 1 | 6 participants (Actual) | Interventional | 2019-05-01 | Terminated (stopped due to Sponsor discontinued the drug) | ||
| A Phase I/II Study of Entinostat in Combination With 5-Azacytidine in Patients With Recurrent Advanced Non-Small Cell Lung Cancer[NCT00387465] | Phase 1/Phase 2 | 94 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| Phase 1b/2a Safety and Immunogenicity of the DNMT Inhibitor Azacitidine During Anti-Tuberculosis Therapy[NCT03941496] | Phase 1/Phase 2 | 0 participants (Actual) | Interventional | 2022-10-31 | Withdrawn (stopped due to The study was halted prematurely due to Bristol-Myers Squibb's (BMS) decision to withdraw support for this study.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
DLT is defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v3.0 (NCT00387465)
Timeframe: Up to 28 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Phase I - 30mg/m2 Azacitidine | 0 |
| Phase I - 40mg/m2 Azacitidine | 0 |
"Number of participants with decrease in DNA methylation (methylation-signature positive) on Day 10 or Day 29, and either stable disease or objective response (OR) as defined by RECIST 1.0. Per RECIST 1.0, progression is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; PR is defined as >=30% decrease in the sum of the longest diameter of target lesions, complete response is defined as disappearance of all target lesions; OR=CR+PR." (NCT00387465)
Timeframe: Baseline and days 10 and 29
| Intervention | Participants (Count of Participants) |
|---|---|
| Azacitidine 40mg/m2 With Entinostat | 8 |
Determined by the method determined by Kaplan and Meier. 95% confidence intervals will be estimated. (NCT00387465)
Timeframe: Up to 1 year
| Intervention | months (Median) |
|---|---|
| Azacitidine 40mg/m2 With Entinostat | 6.4 |
(NCT00387465)
Timeframe: Day 1
| Intervention | ng*hr/mL (Mean) |
|---|---|
| Azacitidine 40mg/m2 With Entinostat | 675 |
Maximal concentration (ng/mL) of azacitidine (NCT00387465)
Timeframe: Day 1
| Intervention | ng/mL (Mean) |
|---|---|
| Azacitidine 40mg/m2 With Entinostat | 468 |
(NCT00387465)
Timeframe: Day 1
| Intervention | hours (Mean) |
|---|---|
| Azacitidine 40mg/m2 With Entinostat | 1.12 |
Time to maximal concentration of azacitidine in the blood. (NCT00387465)
Timeframe: Day 1
| Intervention | hours (Median) |
|---|---|
| Azacitidine 40mg/m2 With Entinostat | 0.5 |
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Determined by the method determined by Kaplan and Meier. 95% confidence intervals will be estimated. (NCT00387465)
Timeframe: Up to 1 year
| Intervention | weeks (Median) |
|---|---|
| Azacitidine 40mg/m2 With Entinostat | 7.4 |
(NCT00387465)
Timeframe: Day 10 and 17
| Intervention | ng/mL (Mean) | |
|---|---|---|
| Day 10 | Day 17 | |
| Azacitidine 40mg/m2 With Entinostat | 0.84 | 1.10 |
3 reviews available for entinostat and Lung Neoplasms
| Article | Year |
|---|---|
Participation of the Fas/FasL signaling pathway and the lung microenvironment in the development of osteosarcoma lung metastases.
Topics: Animals; Antineoplastic Agents; Benzamides; Bone Neoplasms; Deoxycytidine; Epigenesis, Genetic; Fas | 2014 |
Entinostat (SNDX-275) for the treatment of non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Epigenesis, Genetic; His | 2015 |
Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies.
Topics: Antibodies, Monoclonal; Azacitidine; Azetidines; Benzamides; Biomarkers, Tumor; Carcinoma, Non-Small | 2016 |
4 trials available for entinostat and Lung Neoplasms
| Article | Year |
|---|---|
Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer, ETCTN 10399.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Carboplatin; Etoposide; Femal | 2023 |
Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti-PD-(L)1 Therapy.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2021 |
Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Cadherins; Carc | 2012 |
Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Cadherins; Carc | 2012 |
Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Cadherins; Carc | 2012 |
Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Cadherins; Carc | 2012 |
Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzamides; Bi | 2011 |
Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzamides; Bi | 2011 |
Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzamides; Bi | 2011 |
Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzamides; Bi | 2011 |
18 other studies available for entinostat and Lung Neoplasms
| Article | Year |
|---|---|
Entinostat Enhances the Efficacy of Chemotherapy in Small Cell Lung Cancer Through S-phase Arrest and Decreased Base Excision Repair.
Topics: Apoptosis; Cell Line, Tumor; Cisplatin; DNA Repair; Histone Deacetylase Inhibitors; Humans; Lung Neo | 2023 |
Combination Effect of Silver Nanoparticles and Histone Deacetylases Inhibitor in Human Alveolar Basal Epithelial Cells.
Topics: A549 Cells; Antineoplastic Agents; Apoptosis; Benzamides; Caspase 3; Cell Survival; DNA Fragmentatio | 2018 |
MS-275 potentiates the effect of YM-155 in lung adenocarcinoma via survivin downregulation induced by miR-138 and miR-195.
Topics: A549 Cells; Adenocarcinoma of Lung; Animals; Benzamides; Cell Line, Tumor; Cell Proliferation; Cell | 2019 |
The histone deacetylase inhibitor, MS-275 (entinostat), downregulates c-FLIP, sensitizes osteosarcoma cells to FasL, and induces the regression of osteosarcoma lung metastases.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; Bone Neoplasms; CASP8 and | 2013 |
Histone deacetylase inhibition overcomes drug resistance through a miRNA-dependent mechanism.
Topics: Acetyltransferases; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Humans; | 2013 |
Aerosolised 5-azacytidine suppresses tumour growth and reprogrammes the epigenome in an orthotopic lung cancer model.
Topics: Administration, Inhalation; Aerosols; Animals; Antimetabolites, Antineoplastic; Azacitidine; Benzami | 2013 |
FBXW7 mediates chemotherapeutic sensitivity and prognosis in NSCLCs.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Agents; Benzamides; Carcinoma, No | 2014 |
SGI-110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzami | 2014 |
Evaluation of azacitidine and entinostat as sensitization agents to cytotoxic chemotherapy in preclinical models of non-small cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzamides; Camptothecin; Carc | 2015 |
Take two: Combining immunotherapy with epigenetic drugs to tackle cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzamides; Car | 2016 |
MicroRNA-mediated epigenetic targeting of Survivin significantly enhances the antitumor activity of paclitaxel against non-small cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; DN | 2016 |
Targeting SALL4 by entinostat in lung cancer.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Survival; Disease Models, Animal; | 2016 |
Rescue of major histocompatibility-DR surface expression in retinoblastoma-defective, non-small cell lung carcinoma cells by the MS-275 histone deacetylase inhibitor.
Topics: Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Histone Deacety | 2009 |
Induction of E-cadherin in lung cancer and interaction with growth suppression by histone deacetylase inhibition.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Benzoquinones; Blotting, Western; Cadherins; | 2009 |
Combination therapy with vidaza and entinostat suppresses tumor growth and reprograms the epigenome in an orthotopic lung cancer model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Benzamides; Cell Li | 2011 |
Effect of the histone deacetylase inhibitor SNDX-275 on Fas signaling in osteosarcoma cells and the feasibility of its topical application for the treatment of osteosarcoma lung metastases.
Topics: Administration, Inhalation; Animals; Base Sequence; Benzamides; Blotting, Western; Cell Line, Tumor; | 2011 |
Smoking induces epithelial-to-mesenchymal transition in non-small cell lung cancer through HDAC-mediated downregulation of E-cadherin.
Topics: Acetylation; Antigens, CD; Benzamides; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Movement; Dow | 2012 |
Bombesin/gastrin-releasing peptide receptor antagonists increase the ability of histone deacetylase inhibitors to reduce lung cancer proliferation.
Topics: Animals; Benzamides; Cell Line, Tumor; Cell Proliferation; Formazans; Genes, Tumor Suppressor; Histo | 2006 |